{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:56:05Z","timestamp":1789674965562,"version":"4.0.1"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015396","name":"Thailand Center of Excellence for Life Sciences","doi-asserted-by":"publisher","award":["TC3\/62"],"award-info":[{"award-number":["TC3\/62"]}],"id":[{"id":"10.13039\/100015396","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program Management Unit for Competitiveness, Thailand Science Research and Innovation","award":["1963054"],"award-info":[{"award-number":["1963054"]}]},{"name":"Fundamental Fund, Thailand Science Research and Innovation","award":["FRB650007\/0185"],"award-info":[{"award-number":["FRB650007\/0185"]}]},{"name":"Research Chair Grant, National Science and Technology Development Agency, Thailand","award":["FDA-CO-2559-3325-TH"],"award-info":[{"award-number":["FDA-CO-2559-3325-TH"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy. Their remarkable antitumor effect has exerted complete remission in treating B-cell malignancies. Although successful patient treatment has been shown, improvement to the structure of CAR to enhance its safety and efficacy profile is warranted. Transduction with a lentiviral vector (LVV) leading to the expression of CARs is also a critical step in redirecting T cells to target specific tumor antigens. To improve the efficacy of CD19 CARs in this study, the transduction ability of second and third generations LVV were compared. Ex vivo expansion of CD19 CARs T cells from healthy donors\u2019 peripheral blood mononuclear cells was performed after transduction of T cells with second and third generations LVV. Transduction efficacy of transduced T cells was determined to show a higher percentage in the third generations LVV transduced cells, with no changes in viability and identity of cells characterized by immunophenotyping. Testing the cytotoxic capacity of third generations LVV-transduced T cells against target cells showed higher reactivity against control cells. Cytokine expression was detected on the CD19 CARs T cells, suggesting that these cells limit in vitro growth of B-cell leukemia via secretion of the pro-inflammatory cytokine IFN \u03b3. To investigate whether the third generation LVV transduced T cells can limit CD19 lymphoma growth in vivo, an analysis of tumor burden in a mouse model assessed by bioluminescence imaging was performed. We found that, in the presence of CD19 CARs T cells, the level of tumor burden was markedly reduced. In addition, an increase in the length of survival in mice receiving CAR-CD19 T cells was also observed. This suggests that transduction with third generations LVV generate a functional CAR-CD19 T cells, which may provide a safer and effective therapy for B-cell malignancies.<\/jats:p>","DOI":"10.1371\/journal.pone.0281735","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T19:29:04Z","timestamp":1676316544000},"page":"e0281735","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models"],"prefix":"10.1371","volume":"18","author":[{"given":"Piamsiri","family":"Sawaisorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korakot","family":"Atjanasuppat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitipong","family":"Uaesoontrachoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-8987","authenticated-orcid":true,"given":"Parin","family":"Rattananon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Worapapar","family":"Treesuppharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2791-7471","authenticated-orcid":true,"given":"Usanarat","family":"Anurathapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"issue":"3","key":"pone.0281735.ref001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/10428190701882179","article-title":"Treatment of acute lymphoblastic leukemia in low- and middle-income countries: challenges and opportunities","volume":"49","author":"R Ribeiro","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"10230","key":"pone.0281735.ref002","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"F Malard","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"pone.0281735.ref003","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"H Inaba","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"pone.0281735.ref004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ped.13457","article-title":"Treatment and biology of pediatric acute lymphoblastic leukemia","volume":"60","author":"M Kato","year":"2018","journal-title":"Pediatr Int"},{"issue":"16","key":"pone.0281735.ref005","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"V Conter","year":"2010","journal-title":"Blood"},{"issue":"2","key":"pone.0281735.ref006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2009.257","article-title":"Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000","volume":"24","author":"A Moricke","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"pone.0281735.ref007","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/SCS.0b013e318175b4c9","article-title":"Psychological rehabilitation of pediatric burn patients","volume":"19","author":"TJ Nguyen","year":"2008","journal-title":"J Craniofac Surg"},{"issue":"12","key":"pone.0281735.ref008","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2014.142","article-title":"A revised definition for cure of childhood acute lymphoblastic leukemia","volume":"28","author":"CH Pui","year":"2014","journal-title":"Leukemia"},{"issue":"9757","key":"pone.0281735.ref009","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"C Parker","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"pone.0281735.ref010","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/sj.leu.2403874","article-title":"Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia","volume":"19","author":"L Roy","year":"2005","journal-title":"Leukemia"},{"issue":"14","key":"pone.0281735.ref011","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"G Tallen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"pone.0281735.ref012","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"CE Thomas","year":"2003","journal-title":"Nat Rev Genet"},{"issue":"2","key":"pone.0281735.ref013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00005-010-0063-4","article-title":"Lentiviral vectors in gene therapy: their current status and future potential","volume":"58","author":"D Escors","year":"2010","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"16","key":"pone.0281735.ref014","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"SL Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0281735.ref015","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"CJ Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"7","key":"pone.0281735.ref016","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"MC Milone","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"pone.0281735.ref017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/ajco.13474","article-title":"Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL","volume":"18","author":"S Prasongtanakij","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"pone.0281735.ref018","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/hgtb.2011.199","article-title":"A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes","volume":"23","author":"S Yang","year":"2012","journal-title":"Hum Gene Ther Methods"},{"key":"pone.0281735.ref019","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev-bioeng-071813-104938","article-title":"Viral Vectors for Gene Therapy: Translational and Clinical Outlook","volume":"17","author":"MA Kotterman","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"issue":"4","key":"pone.0281735.ref020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/d41573-021-00044-4","article-title":"Towards improved viral vectors for gene therapy","volume":"20","author":"S. Crunkhorn","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"pone.0281735.ref021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"MH Kershaw","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"pone.0281735.ref022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18388\/abp.2009_2490","article-title":"Use of HIV as a gene transfer vector","volume":"56","author":"K Pluta","year":"2009","journal-title":"Acta Biochim Pol"},{"issue":"6","key":"pone.0281735.ref023","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.MAT.0000093747.89681.4C","article-title":"Lentiviral vector: a useful tool for transduction of human liver endothelial cells","volume":"49","author":"T Totsugawa","year":"2003","journal-title":"ASAIO J"},{"issue":"4","key":"pone.0281735.ref024","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2002-07-2238","article-title":"Lentiviral vector transduction of NOD\/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis","volume":"101","author":"NB Woods","year":"2003","journal-title":"Blood"},{"issue":"16","key":"pone.0281735.ref025","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"SA Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0281735.ref026","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"JN Kochenderfer","year":"2009","journal-title":"J Immunother"},{"issue":"9967","key":"pone.0281735.ref027","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"DW Lee","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"pone.0281735.ref028","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"U Anurathapan","year":"2014","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0281735.ref029","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression","volume":"35","author":"K Fousek","year":"2021","journal-title":"Leukemia"},{"key":"pone.0281735.ref030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40425-017-0246-1","article-title":"A tandem CD19\/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines","volume":"5","author":"D Schneider","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0281735.ref031","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"R Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"pone.0281735.ref032","doi-asserted-by":"crossref","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","article-title":"IFN-\u03b3: A cytokine at the right time, is in the right place","volume":"43","author":"JD Burke","year":"2019","journal-title":"Semin Immunol"},{"issue":"2","key":"pone.0281735.ref033","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"JN Brudno","year":"2020","journal-title":"Nat Med"},{"key":"pone.0281735.ref034","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","article-title":"Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells","volume":"9","author":"A Dwivedi","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"pone.0281735.ref035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"JN Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0281735.ref036","doi-asserted-by":"crossref","first-page":"584","DOI":"10.21037\/atm.2020.02.148","article-title":"Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy","volume":"8","author":"SI Hu","year":"2020","journal-title":"Ann Transl Med"},{"issue":"6","key":"pone.0281735.ref037","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"HM Finney","year":"1998","journal-title":"J Immunol"},{"issue":"4","key":"pone.0281735.ref038","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"C Imai","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"pone.0281735.ref039","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"A Krause","year":"1998","journal-title":"J Exp Med"},{"issue":"11","key":"pone.0281735.ref040","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"A Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T19:29:37Z","timestamp":1676316577000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0281735"}},"subtitle":[],"editor":[{"given":"Sumit Kumar","family":"Hira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0281735","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]}}}